Maxwell Biomedical announced that it has initiated its First-In-Human Clinical Trial “Initial Experience with Spatial Resynchronization Therapy in Patients with Atrial Fibrillation (SR-TheAF)”

More in Rhythm:

• Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China November 25, 2024
• Results from Cardiosense’s SEISMIC-HF I Study of a Machine Learning Model to Non-Invasively Assess Cardiac Filling Pressure Presented as Late-Breaking Science at American Heart Association’s 2024 Scientific Sessions November 20, 2024
• New Data Demonstrates Vektor Medical’s AI-Powered vMap Algorithm Achieves 91% Accuracy in Distinguishing Epicardial and Endocardial Ventricular Tachycardia, Markedly Surpassing Visual ECG Analysis November 15, 2024